MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » GI Dynamics touts more clinical trials data

GI Dynamics touts more clinical trials data

By

GI Dynamics logo

GI Dynamics Inc. is once again touting positive data from clinical trials of its EndoBarrier gut liner, confirming earlier data showing that the device helps reduce the symptoms of Type II diabetes and helps obese patients lsoe weight.

The Lexington, Mass.-based startup cited a pair of studies, one involving obese patients and another involving obese Type II diabetics, examining its EndoBarrier gastrointestinal liner. The device is a plastic sleeve that’s inserted via endoscope into the small intestine, where it slows the absorption of food nutrients.

The studies enrolled 61 patients and monitored them for weight loss or gain and also monitored 22 diebetic patients for a common measure of the amount of glycated hemoglobin, or HbA1c. Those patients, who entered the study with a mean body mass index of 44.9 and mean baseline blood sugar levels of 8.9 percent HbA1c, showed a drop of 1.5 percent HbA1c after 24 weeks, with 58 percent achieving HbA1c levels of 7 percent or less. All patients in the studies showed a mean weight loss of about 33 pounds.

One patient’s device migrated during the study before the end of 24 weeks, which GI Dynamics called "a significant improvement" over the first-generation design of the device, according to a press release. Eight other EndoBarriers were removed early due to "device-related adverse events such as GI discomfort," according to the release.

It’s the latest round of positive clinical data for GI Dynamics, which in March announced that its first batch of patients passed the one-year mark. The results showed that patients lost an average of 35 pounds and showed an average 2.5-point drop in HbA1c, one year into using the device.

The company announced similarly positive results in November 2009, when a group of 19 patients passed the 24-week mark. The EndoBarrier won CE Mark approval the next month, clearing the way for sales to begin within the European Union this year. Earlier in 2009 GI Dynamics also closed on $15 million in Series C funding from a host of investors, including Waltham, Mass.-based Polaris Venture Partners and Johnson & Johnson Development Corp., the private-equity arm of the healthcare giant J&J (NYSE:JNJ). And early this year Medtronic Inc. (NYSE:MDT) put $15 million into GI Dynamics’ coffers.

In case you missed it

RSS From Medical Design & Outsourcing

  • What Laura Mauri learned from a ‘firestorm’ in her first months at Medtronic
    Dr. Laura Mauri faced a monumental moment with former Medtronic CEO Omar Ishrak shortly after she joined the company as VP of global clinical research and analytics. It was late 2018, and Mauri — who’s now an SVP and the chief scientific, medical and regulatory officer at Medtronic (NYSE: MDT) — was in a meeting… […]
  • Senators seek post-market FDA study of pulse oximeters and skin color
    Democratic U.S. senators are prodding the FDA to launch a post-market study of pulse oximeters due to unreliable performance for patients with dark skin. Pulse oximeters estimate blood oxygen levels (SpO2) and pulse rates in patients using infrared light — usually on a fingertip — at home or in clinical settings. Blood oxygenation is one… […]
  • TE Connectivity opens global medical device prototyping center in Ireland
    TE Connectivity (NYSE:TEL) today announced it opened its global Propelus Prototype Center for medical devices in Galway, Ireland. The $5 million rapid prototyping center was built into its existing manufacturing site in Galway and directly connects TE engineers with customers to reduce development time and increase speed to market for lifesaving and life-improving medical devices. Propelus… […]
  • Contract manufacturer Minnetronix Medical launches its first in-house product, MindsEye
    Minnetronix Medical has launched MindsEye, making it the first medical device that the contract developer and manufacturer has conceived and commercialized. St. Paul-based Minnetronix Medical’s MindsEye is the first expandable brain access port on the market. The FDA cleared the device under the 510(k) pathway in August 2020. The minimally invasive device gives neurosurgeons deep… […]
  • What’s next for Jennifer Fried after leaving Explorer Surgical?
    Explorer Surgical co-founder Jennifer Fried has resigned from the company after selling it to Global Healthcare Exchange in October. Fried announced her departure last week on LinkedIn, saying she’s preparing for her next professional chapter. “It’s bittersweet — I’m so proud of everything our team has built and accomplished,” Fried wrote. “The time has flown… […]
  • The 24 best medical device innovations of 2022
    The Galien Foundation recently announced its nominees of medical device innovations for its 2022 Prix Galien USA awards. There are 24 medical technologies nominated for the annual award this year, up from 18 nominees in 2021. The Galien Foundation’s annual Prix Galien awards highlight devices, biotechnology and pharmaceutical products designed to improve the human condition.… […]
  • FDA issues new COVID-19 testing guidance to avoid false negatives
    COVID-19 testing should be repeated following a negative result on any antigen test, the FDA said in a move that could increase demand for diagnostics manufacturers. The latest guidance from the federal health agency is for negative COVID-19 antigen test results regardless of the presence or absence of symptoms. The federal agency said recent studies… […]
  • Confluent Medical expands Costa Rica manufacturing footprint for nitinol, complex catheter production
    Confluent Medical Technologies this week announced the opening of its new addition to its Costa Rica manufacturing facility. The expansion adds 66,000 sq. ft to its large-scale manufacturing center of excellence in Alajuela, Costa Rica to expand Confluent’s capacity for nitinol component processing and complex catheter manufacturing. “Confluent has experienced consistent and strong growth in… […]
  • FDA’s breakthrough medical device designations tally nears 700
    Stewart Eisenhart, Emergo Group The US Food and Drug Administration has granted almost 700 designations over the past seven years under a voluntary program for expedited regulatory review of medical devices and combination products that facilitate more effective treatment or diagnosis of serious diseases. According to recent metrics published by FDA, the agency has issued a total of… […]
  • Lifecore Biomedical’s owner plans to go all-in on contract development and manufacturing
    Lifecore Biomedical parent company Landec Corp. (Nasdaq:LNDC) plans to take the subsidiary’s name, leadership and headquarters as its own and sell off food businesses to focus on contract development and manufacturing. Santa Maria, California-based Landec said it will rename itself as Lifecore Biomedical “in the near future” and change its Nasdaq ticker to LFCR. Landec… […]
  • COVID-19 immunity test developers at MIT seek diagnostic manufacturer
    MIT researchers have developed a device for predicting an individual’s COVID-19 immunity and are looking for a diagnostic company to get it manufactured in large numbers and approved by the FDA. The lateral flow test uses the same technology as at-home rapid antigen COVID-19 tests to measure neutralizing antibodies for SARS-CoV-2 in a blood sample,… […]

Leave a Reply